The objective of this study was to obtain information to guide prevention, detection, and treatment of viral hepatitis in a county jail population. Hepatitis A, B, and C serology and alanine aminotransferase levels (ALT) were combined with health information for 463 persons tested at intake in 1999. Prevalence of hepatitis A antibodies was 21.6%. Overall hepatitis B seroprevalence was 26.1%, 17.9% for past or present disease. Serological evidence of hepatitis B vaccination was found in 40% of inmates younger than 20 years but in only 3.9% of those 20 years and older. Prevalence of hepatitis C antibody was 20.7%. Of those, 86.5% were unaware of their diagnosis and 58% used alcohol. Multivariate predictors of hepatitis were sharing needles, elevated ALT, and a history of hepatitis. Hepatitis C accounted for the majority of elevated ALT, with alcohol use a distant second. Overall, the need for hepatitis A and B vaccination remains the rule. Various screening models are presented. General use of ALT testing on intake could contribute significantly to diagnosis of hepatitis C and other liver disease and be used in a simple testing algorithm that identifies most persons with hepatitis C while testing the minority.
Allen, S. A., Spaulding, A. C., Osei, A. M., Taylor, L. E., Cabral, A. M., & Rich, J. D. (2003). Treatment of chronic hepatitis C in a state correctional facility. Annals of Internal Medicine, 138, 187-190.
2.
Alter, M. J., Kruszon-MoranD., Nainan, O. V., McQuillan, G. M., GaoF., Moyer, L. A., et al. (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine, 341, 556-562.
3.
AwofesoN. (2002). Hepatitis B vaccination in prisons. Bulletin of the World Health Organization, 80, 569-574.
4.
BabudieriS., LongoB., SarmatiL., StarniniG., DoriL., SuligoiB., et al. (2005). Correlates of HIV, HBV, and HCV infections in a prison inmate population: Results from a multicentre study in Italy. Journal of Medical Virology, 76, 311-317.
5.
BaillargeonJ., WuH., Kelley, M. J., GradyJ., LinthicumL., & DunnK. (2003). Hepatitis C sero-prevalence among newly incarcerated inmates in the Texas correctional system. Public Health, 117, 43-48.
6.
BergT., SarrazinC., HerrmannE., HinrichsenH., GerlachT., ZachovalR., et al. (2003). Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology, 37, 600-609.
7.
Conklin, T. J., LincolnT., & Flanigan, T. P. (1998). A public health model to connect correctional health care with communities. American Journal of Public Health, 88, 1249-1250.
8.
Conklin, T. J., LincolnT., & Tuthill, R. W. (2000). Self-reported health and prior health behaviors of newly admitted correctional inmates. American Journal of Public Health, 90, 1939-1941.
9.
Conklin, T. J., LincolnT., WilsonR., & GramarossaG. (2002). A public health manual for correctional health care. Ludlow, MA: Hampden County Sheriff’s Department.
10.
EastmanE., RappaportE., DeMariaA., & WernerB. (2001, October). Validation of self-reported risk as a method for identifying anti-hepatitis C positive individuals at time of intake physical examination at Massachusetts Department of Correction facilities. Paper presented at the 129th Annual Meeting of the American Public Health Association, Atlanta, GA.
11.
Gandhi, R. T., WurcelA., LeeH., McGovernB., BoczanowskiM., GerwinR., et al. (2003). Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clinical Infectious Diseases, 36, 1602-1605.
12.
Gandhi, R. T., WurcelA., LeeH., McGovernB., ShopisJ., GearyM., et al. (2005). Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: Implications for hepatitis B vaccine strategies. Journal of Infectious Diseases, 191, 1435-1441.
13.
Goldstein, S. T., Alter, M. J., Williams, I. T., Moyer, L. A., Judson, F. N., MottramK., et al. (2002). Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: Implications for vaccination programs. Journal of Infectious Diseases, 185, 713-719.
14.
Hammett, T. M., Harmon, M. P., & RhodesW. (2002). The burden of infectious disease among inmates of and releasees from U.S. correctional facilities, 1997. American Journal of Public Health, 92, 1789-1794.
15.
Hui, C. K., BelayeT., MontegrandeK., & Wright, T. L. (2003). A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. Journal of Hepatology, 38, 511-517.
16.
Jacobs, R. J., SaabS., Meyerhoff, A. S., & Koff, R. S. (2003). An economic assessment of pre-vaccination screening for hepatitis A and B. Public Health Reports, 118, 550-558.
17.
Macalino, G. E., VlahovD., Sanford-ColbyS., PatelS., SabinK., SalasC., et al. (2004). Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. American Journal of Public Health, 94, 1218-1223.
18.
Mark, K. E., Murray, P. J., Callahan, D. B., & Gunn, R. A. (2003, October). Follow-up of patients diagnosed with hepatitis C through STD clinic and HIV test site screening programs—San Diego, California, 1999-2003 (Abstract 602). Poster presented at the annual meeting of the Infectious Diseases Society of America, San Diego, CA.
19.
Massachusetts Department of Public Health. (2004). Hepatitis A: The outbreak continues. Communicable Disease Update: Newsletter of the Bureau of Communicable Disease Control, Massachusetts Department of Public Health, 12(4), 2-2.
20.
National Commission on Correctional Health Care. (2002). The health status of soon-to-be-released inmates: A report to Congress. Chicago: Author.
21.
NeiferS., MolzB., SuckerU., KreuzpaintnerE., WeinbergerK., & JilgW. (1997). High percentage of isolated anti-HBc-positive persons among prisoners. Gesundheitswesen, 59, 409-412.
22.
Pasko, M. T., & Beam, T. R., Jr. (1990). Persistence of anti-HBs among health care personnel immunized with hepatitis B vaccine. American Journal of Public Health, 80, 590-593.
23.
Pfister, J. R., HasseB., HurieM., Davis, J. P., VoermansP., & ThorpeC. (2001, Spring). Targeted hepatitis C virus screening of inmates on admission to the Wisconsin adult correctional system. Wisconsin AIDS/HIV Update.
24.
PisuM., Meltzer, M. I., & LyerlaR. (2002). Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine, 21, 312-321.
25.
Protection Against Viral Hepatitis: Recommendations of the Immunization Practices Advisory Committee. (1990). MMWR Recommendations and Reports, 39(RR-2), 1-26.
26.
QuaglioG., LugoboniF., VentoS., LechiA., AccordiniA., BossiC., et al. (2001). Isolated presence of antibody to hepatitis B core antigen in injection drug users: Do they need to be vaccinated?. Clinical Infectious Diseases, 32, E143-E144.
27.
Rodriguez-Mendez, M. L., Gonzalez-QuintelaA., AguileraA., & BarrioE. (2000). Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. American Journal of Gastroenterology, 95, 1316-1322.
28.
Ruiz, J. D., Chang, J. S., BernsteinK., Chow, J. M., BolanG., PettiforA., et al. (2001). Prevalence of HIV infection, sexually transmitted diseases, hepatitis, and risk behaviors among inmates entering prison at the California Department of Corrections, 1999. Sacramento: California Department of Health Services, Office of AIDS, HIV/AIDS Epidemiology Office.
29.
ShostakG. (2001). Massachusetts Department of Youth Services program description listed by the Immunization Action Coalition. Retrieved October 28, 2001, from www.hepprograms.org/juven/juven3.htm
30.
SolomonL., FlynnC., MuckK., & VertefeuilleJ. (2004). Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. Journal of Urban Health, 81, 25-37.
31.
SpauldingA., GreeneC., DavidsonK., SchneidermannM., & RichJ. (1999). Hepatitis C in state correctional facilities. Preventive Medicine, 28, 92-100.
32.
TorbensonM., KannangaiR., AstemborskiJ., Strathdee, S. A., VlahovD., & Thomas, D. L. (2004). High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology, 39, 51-57.
33.
U. S. Preventive Services Task Force. (2004). Screening for hepatitis C virus infection in adults: Recommendation statement. Annals of Internal Medicine, 140, 462-464.
34.
WeinbaumC., LyerlaR., & Margolis, H. S. (2003). Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recommendations and Reports, 52(RR-1), 1-36.
35.
Weinhardt, L. S., Carey, M. P., Johnson, B. T., & Bickham, N. L. (1999). Effects of HIV counseling and testing on sexual risk behavior: A meta-analytic review of published research, 1985-1997. American Journal of Public Health, 89, 1397-1405.
36.
Wurcel, A. G., BicaI., Gandhi, R. T., BradleyM., GalvinS., KimA., et al. (2003, October). Acute hepatitis C (HCV) in incarcerated patients with history of intravenous drug use (Abstract 592). Poster presented at the annual meeting of the Infectious Disease Society of America, San Diego, CA.
